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Previous studies have shown that heat shock proteins (HSPs) were upregulated in various types of tumors and
were associated with histological grade, recurrence and metastasis of malignant tumors. In this study, we investi-
gated whether heat shock protein 70 kDa (HSP70) was associated with histological grade of laryngeal squamous
cell carcinomas (LSCC). We also determine the role of HSP70 in LSCC radiation resistance using a laryngeal carci-
noma xenograft model by antisense HSP70 RNA technique. Immunohistochemistry data showed that HSP70 was
detected in 96% of LSCC tissues (48 out of 50). The expression level of HSP70 was significantly lower in early stage
of LSCC than that in late stage (P = 0.015). Radiation treatment result showed that the volumes and weights of
implantation tumors in the group injected with antisense HSP70 oligos were significantly reduced comparing to
the group injected with random oligos(p < 0.05). In addition, cleavage and degradation of tumor nucleolin in anti-
sense HSP70 oligos injection group was significantly higher than that in random oligos injection group. Our result
suggested that HSP70 may play a role in LSCC radiotherapy resistance by inhibiting cleavage and degradation of
nucleolin.
Introduction
HSP70 is the most important member of heat shock
protein family, and plays an important role in the cells
endogenous protection mechanisms [1,2]. Recent studies
have shown that different type of heat shock protein
upregulated in different type of tumors, HSPs were asso-
ciated with histological grade, recurrence and metastasis
of malignant tumors [3-6]. However, the role of HSP70
in LSCC is not fully understood.
Weber, A et al h a dr e p o r t e dt h a tH S P 7 0w a ss i g n i f i -
cantly upregulated in squamous cell carcinoma of the
head and neck (SCCHN) [7]. In our previous studies, we
also found that HSP70 highly expressed at 7.7 folds
comparing to normal tissue using HG-U133.Plus.2.0
chip (data unpublished). These results suggested that
the overexpression of HSP70 was an important biologi-
cal characteristic of LSCC.
Nucleolin(C23) is an abundant nuclear protein located
in the dense fibrillar components(DFCs) and granular
components(GCs) of nucleoli. It plays essential roles in
promoting cell proliferation [8-11]. Our previous studies
have shown that HSP70 could interact with C23 and
inhibiting H2O2-induced cleavage and degradation of
C23, thereby inhibiting reactive oxygen species-induced
cell apoptosis [12]. There were two ways for radiother-
apy to destruct tumor cells: (1) X-ray directly broke the
DNA of the cancer cells into fragmentations, leading to
cell apoptosis; (2) X-ray released free radicals from
other components (e.g. H2O) in the cells thereby to
attack tumor cells. Theoretically, radiotherapy could
result in cleavage and degradation of C23 and sequen-
tially kill the tumors.
In the present study, we determined whether reduc-
tion of HSP70 expression could enhance radiosensitivity
of LSCC by increasing C23 cleavage and degradation.
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Tissue Microarray
High-quality tissue microarray (TMA) was constructed
with fifty tumor samples including different stages of
LSCC. The clinicopathologic features of the participants
included in this analysis were presented in Table 1.
Briefly, serial 5-μm sections were cut from each of the
donor blocks. One of these sections was stained with
hematoxylin and eosin staining (H&E) to mark morpho-
logically representative areas of the tumor. Two areas in
each case were targeted. Tissue cylinders with a dia-
meter of 0.6 mm were punched from the two targeted
areas in each donor block and deposited into a 14 × 7
+2 (100 cores) TMA block, which contained 50 cores of
tumor tissues. At last we gained 80 slides of high-quality
TMA. Immunostaining for HSP70 protein was per-
formed by using TMAs.
RNA oligos
According to the design principle of oligodexynucleotide
(ODN) probes described by Myers KJ and Branch AD
[13,14], three antisense-ODNs (ASODNs) were designed
artificially against the HSP70 mRNA complete sequence
(GeneBank NO.BC002453) from http://www.ncbi.nlm.
nih.gov/. Three ASODNs were synthesized with phos-
phorothioate modification by Bioasia Co. Ltd. (Shanghai,
China). After screening an effective ASODN, AS-1(5′-X
TGTTTTCTTGGCCAT -3′), which complemented to
the first 20 coding sequences of HSP70 mRNA, random
oligos (5′-X GATTATCGTGTTGTTACT -3′) were used
as negative controls against AS-1, X represents green
fluorescent marker.
Animals and treatment
BALB/c female mice (18-22 g, 4-6 weeks) were obtained
from Laboratory Animal Centre, Xiangya School of
Medicine, Central South University (changsha, China).
The animals were housed for 1 week prior to experi-
ment. The animal experiments were undertaken within
the guidelines of regulations for the use of experimental
animals of Central South University. The animals were
injected with 2 × 10
6 Hep-2 cells to establish the
implantation tumor model of LSCC. When the implan-
tation tumor grew up to 100 mm
3, the nude mice were
randomly divided into group antisense and group ran-
dom. Each group has eight mice. Group antisense was
injected with antisense oligos and group random was
injected with random oligos. In all experiments, unless
otherwise stated, the mice were administered with RNA
oligos through intratumoral injection at the dose of 100
μg per 0.1 ml/injection at 7th, 10th and 14th day after
tumor cells implantation. Three days after the final
injection, all the mice accepted one single dose (5Gy)
whole body radiation. The tumor volumes were mea-
sured twice a week using the formula: V = π/6 × (larger
diameter) × (smaller diameter)
2 , as reported previously
[15]. The mice were sacrificed once the tumor appeared
necrosis, the tumor tissues were collected for western-
blot, and paraffin-embedded tissues were used for
immunohistochemistry and TUNEL assay.
Western blot
The total protein was extracted from fresh tissues and
the concentration of protein was determined by using
bicinchoninic acid (BCA) Protein Assay Kit (Pierce,
Rockford, U.S.A.). 100 μg of total protein was separated
at 8% SDS-PAGE by electrophoresis and then trans-
ferred onto nitrocellulose membrane (Millipore, Bed-
ford, U.S.A.). The membranes were blocked with 2%
albumin in TBST (20 mM Tris-HCl, pH 8.0, 150 mM
NaCl, 0.1% Tween-20) overnight at 4°C and then hybri-
dized with the following primary antibodies: anti-HSP70
monoclonal antibody (Santa Cruz, USA), anti-nucleolin
polyclonal antibody (Santa Cruz, USA), anti-b-actin
(Boster Biological Technology, China). The immune
complexes were visualized with DAB staining kit (Boster
Biological Technology, China).
Immunohistochemistry
4 μm tissue sections of implantation tumor samples
were baked at 60°C overnight, deparaffinized in xylene
and rehydrated through graded ethanol. Next, 3% hydro-
gen peroxide was applied to block the endogenous per-
oxidases for 30 minutes and sections were subjected to
microwave heat-induced antigen retrieval in citrate buf-
fer (0.01 M, pH 6.0) at high power for two times, each 7
minutes. After rinsing with phosphate-buffer saline, the
sections were incubated with normal goat serum for 30
minutes at 37°C to block nonspecific binding. The sam-
ples were then incubated at 37°C for 30 minutes with
mouse anti-HSP70 monoclonal antibody (Santa Cruz,
USA) and the second antibody (rabbit anti-mouse anti-
body, MaiXin Bio, Fuzhou, China) for 30 minutes at 37°
C. The streptavidin-biotin-peroxidase complex (SABC)
tertiary system (MaiXin Bio) was used according to the
manufacturer’s instruction. All slides were visualized by
applying 3,3- diaminobenzidine tetrahydrochloride
( D A B )f o r2m i n u t e sa n dt h e nc o u n t e r s t a i n e dw i t h
Table 1 Clinicopathologic characteristics of participants
of TMA
Clinicopathologic characteristics of participants of TMA
Male 45
Female 5
Average Age 61.3 ± 4.2
Stage I, II 21
Stage III, IV 29
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Page 2 of 7hematoxylin. The protein expression of HSP70 was thus
determined as negative and positive. In addition, the
expression levels of the HSP70 were also divided into
low expression one (1+) and high expression one (2+ or
3+).
TUNEL Assay
4 μm tissue sections of tumor samples were baked at 55°
C for half an hour, deparaffinized in xylene and rehy-
drated through graded ethanol, and then incubated in
the solution containing 1 μg/ml proteinase K/10 mM
tris solution for 15 min at Room temperature. After rin-
sing with phosphate-buffer saline (PBS), the sections
were incubated with TUNEL reaction mixture for 60
minutes at 37°C, and then were incubated in 100 μl
anti-FITC-AP conj (converter-AP) for 30 min at 37°C.
After incubation, the slides were covered with 50-100 μl
substrate solution, incubated at room temperature, and
visualized with DAB staining kit. The apoptosis cells
were defined as negative and positive according to
immunohistochemical staining. In addition, the rate of
the apoptosis cells was also divided into low expression
(1+) and high expression (2+ or 3+).
Statistical Analysis
Data were represented as means ± S.E.M. of the number
of independent experiment indicated (n) or experiments
performed on at least three separate occasions. For cyto-
plasmic staining, the intensity of immunohistochemical
staining was measured using a numerical scale (0 = no
expression, 1+ = weak expression, 2+ = moderate
expression, and 3+ = strong expression), and the statis-
tic analysis for cytoplasmic staining was calculated using
the Wilcoxon signed-rank test. A Student’stt e s tw a s
used to compare the volumes and weights of each
group. All statistical analyses were performed by using
the SPSS software package (version 10.0, Chicago, IL,
USA). All tests were two-sided and P < 0.05 was consid-
ered statistically significant.
Results
HSP70 expression in different clinical stages of LSCC
To determine whether HSP70 was associated with histo-
l o g i c a lg r a d eo fL S C C ,w eu s e dt i s s u ea r r a yt od e t e c t
HSP70 expression in fifty LSCC cases including different
stages. The results showed that staining of HSP70 was
predominantly detected in cytoplasm as previously
described [16]. The positive staining of HSP70 (Fig. 1a-
b) was detected in 96% of LSCC tissues (48 out of 50).
HSP70 was undetectable in 4% of LSCC specimens (Fig.
1c). The expression level of HSP70 and the clinical stage
of LSCC were summarized in table 2. 19 out of 29 later
stage patients have moderate expression, while 9 out 29
have strong expression, only 1 has weak expression. On
Figure 1 HSP70 expression in LSCC tissues. High HSP70 expression in late stage of LSCC tissues (a-b) was showed comparing to the low
HSP70 expression in early stage LSCC(c), (d) is the negative control show the specificity of the antibody. HSP70 shows strong expression (scored
as 3+, a), moderate expression (scored as 2+, b), weak expression (scored as 1+, c), and negative expression (scored as 0, d) in cytoplasm(×400).
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Page 3 of 7the other hand, only 3 out 21 earlier stage patients have
strong expression, 10 have moderate expression, the rest
of the patients either have no expression or have weak
expression. The data indicated that the expression levels
of HSP70 protein in early stage cases were significantly
lower than that in late stage cases (P = 0.015) (Wilcoxon
signed-rank test).
Screening the antisense oligodeoxynucleotides (ODNs)
which could downregulate HSP70 expression in Hep-2
cells effectively
Based on the mRNA complete sequence of human
HSP70 (GeneBank accession NO. BC002453), we
designed three antisense oligos (ASODNs) at the differ-
ent sites in human HSP70 sequence (AS-1, AS-2 and
AS-3). After being transfected with HSP70 ASODN for
48 h, the total proteins were isolated and the expression
level of HSP70 was determined by western blot. The
results showed that AS-1 significantly inhibited the
expression of HSP70. Both AS-2 and AS-3, however, did
not show any effect (Fig 2a). All the following experi-
m e n t sw e r et h u sc a r r i e do u tb yu s i n gA S - 1 .A n dt h e
corresponding sense and random oligos were designed
based on AS-1 sequence. Western blot showed that the
random and sense oligos had no repressive effect on the
expression of HSP70 (Fig 2b).
The radiation sensitizing effect of HSP70 antisense oligos
on laryngeal carcinoma
To investigate whether the HSP70 antisense oligos have
radiation sensitizing effect on laryngeal carcinoma xeno-
grafts in vivo, the antisense and random oligos were
injected into tumor through intratumoral injection. The
mice were treated with radiation (5Gy). The treatment
effect was measured. The results showed that there was
no significant difference in the tumor growth between
group antisense (368 ± 129 mm3) and group random
(384 ± 179 mm3) before radiotherapy (P > 0.05, Fig. 3a).
However, eight days after radiotherapy, the volumes and
weights of implantation tumor in group antisense (229
± 28 mm3 and 0.18 ± 0.04 g) were significantly smaller
than that of group random (417 ± 103 mm3 and 0.27 ±
0.05 g) (P < 0.05; Fig. 3b, c, d). To determine the effi-
ciency of intratumoral injection, we used oligos with
green fluorescent marker and observed the tumor under
af l u o r e s c e n c em i c r o s c o p ea f t e rt h ef i r s ti n j e c t i o n .F i g .
3e shows obvious infection efficiency.
HSP70 antisense oligos downregulated the HSP70
expression in laryngeal carcinoma xenografts
To further determine the inhibitory effect of HSP70
antisense oligos on HSP70 expression, HSP70 in each
group was detected by western blot (4e) and immuno-
histochemical staining (Fig.4 a ,b ) .T h er e s u l t ss h o w e d
that HSP70 antisense oligos significantly downregulated
HSP70 expression in laryngeal carcinoma xenografts as
it is shown in both western-blot and immunohistochem-
istry assay.
Cleavage and degradation of C23 by HSP70 antisense
oligos promoted radiation-induced apoptosis
The levels of cleavage and degradation of C23 in each
group were detected by western blot. The results
showed that in the random group, a major immuno-
positive band with an estimated molecular weight of
110-kDa was observed while the staining intensity of the
110-kDa band was decreased in the antisense group (Fig
5a). Moreover, an 80 kDa cleaved band of C23 was
detected in the antisense group while this 80-kDa band
was not detected in the random group (Fig 5a). These
results indicated that HSP70 down-regulation was asso-
ciated with cleavage and degradation of C23. Moreover,
the apoptosis cells in each group were identified by
TUTEL method. The results showed that more
Table 2 Analysis the HSP70 protein expression levels in
early stage LSCC and than in late stage LSCC
HSP70 expression levels
Clinicopathological parameter n 01 +2 +3 + P
stage I - II 21 2 6 10 3
stage III - IV 29 0 1 19 9 0.015
Figure 2 Knock-down effect of HSP70 antisense oligos. Hep-2 cells were transfected with HSP70 antisense oligos (AS) or control oligos
(sense oligos and random oligos) as described under materials and methods. After incubation for 48 h, cells were harvested, lysed. Western-
blotted (WB) with the corresponding antibodies was carried out to show the knock-down effect of AS. AS-1 has the best knock-down effect of
all 3 oligos.
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t h a ti ng r o u pr a n d o m( F i g .5 b ,c ,d ,e ) .T h i sr e s u l ts u g -
gested that HSP70 reduction were associated with clea-
vage and degradation of C23 and tumor cell apoptosis.
Discussion
As one of the most conserved molecular chaperones,
HSP70 is essential for proper folding and assembly of
proteins
1,2. It has been reported that HSP70.1 and
HSP70.3 gene play a key role in the maintenance and
repair of chromosome stability in mouse fibroblast cell
after radiation, the radiosensitivity in HSP gene knock-
out mice is higher than that in wild-type mice [16]. This
indicates HSP70 is an important radiation-resistance
gene. However, this result came from the non-tumor
cell experiment. Herein, we used Hep-2 cell line, which
has a high expression level of endogenous HSP70 pro-
tein, to establish a laryngeal carcinoma xenograft model.
T h eH S P 7 0a n t i s e n s eo l i g o sw a su s e dt ob l o c kH S P 7 0
expression. Our results showed that HSP70 antisense
oligos treatment increased radiation sensitizing activity
in xenograft tumors. These results suggested that
HSP70 may play an important role as a radiotherapy-
resistant gene in laryngeal carcinoma.
It has been shown HSP70 could interact with nucleo-
lin (C23) and inhibit H2O2-induced cleavage and degra-
dation of C23 [10]. C23, a nonhistone nuclear RNA
binding protein, plays an important role in maintaining
the balance between anti-apoptosis and pro-apoptosis
[8,9]. Our study has shown that blocking HSP70 expres-
sion could promote cleavage and degradation the
expression of C23 on laryngeal carcinoma xenograft
after radiotherapy. Nucleolin was cleaved and degraded
during several apoptotic cell models. Previous studies
have showed radiotherapy could induce a typical apop-
totic cell death by breaking nucleolin into fragmenta-
tions [17,18]. Western-blot results of the cleavage and
degradation of nucleolin showed that a cleaved band (80
kDa) of nucleolin appeared after radiotherapy by a single
dose of 5Gy. Cleavage and degradation of nucleolin was
also observed in both group antisense and group ran-
dom which indicated that cleavage and degradation of
nucleolin was a typical response to laryngeal carcinoma
xenograft damage caused by the radiotherapy. The over-
expression of HSP70 inhibited cleavage and degradation
of nucleolin, and induced radiotherapy resistance.
Taken together, our data suggested that cleavage and
degradation of nucleolin were involved in the apoptosis
Figure 3 Effect of HSP70 antisense oligos on radiotherapy of laryngeal carcinoma xenografts. (a) shows the tumor growth curve before
radiation, no difference between the 2 groups were found, the tumor volum were for antisense and random group, respectively (P > 0.05, 368
± 129 mm3vs 384 ± 179 mm3). (b)There was significant difference in tumor volumes after 5Gy radiation (P < 0.05, 229 ± 28 mm3 vs 417 ± 103
mm3) (c) Tumor weights also showed significant difference after 5Gy radiation (P < 0.05, 0.18 ± 0.04 g vs 0.27 ± 0.05 g). (d) showed the
representative sample of group antisense and group random after 5Gy radiation (e) showed the infection efficiency of intratumoral
injection.:100×. n = 8 per group,* < 0.05.
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Page 5 of 7Figure 4 HSP70 expressions in laryngeal carcinoma xenograft were down-regulated by HSP70 antisense oligos. (a) shows HSP70 expression
in implantation tumor treated with random oligos. (b) shows HSP70 expression in implantation tumor treated with HSP70 antisense oligos. (c-d)
shows the representative H&E images in group random negative controls and group antisense; Western blot shows hsp70 expressions in group
antisense and group random (e). HSP70 expression is significantly reduced in the antisense group comparing with random group.
Figure 5 Expression levels of HSP70 and cleavage and down-regulation of C23. (a) Western blot detected HSP70 and C23 expression in
group antisense and group random; (b-c) the representative images of TUNEL assay in group antisense and group random; (d-e) The
representative H&E images in group antisense and group random negative controls (×400).
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apy resistance gene by inhibiting the cleavage and degra-
dation of nucleolin.
Since the complex nature of the mechanisms in apop-
tosis and the multi-functionality of HSP70, there are
still several questions remain to be answered inorder to
address the role of HSP70 in radiation resistance. One
interesting question is which domain of HSP70 is
involved in the cleavage and degradation of nucleolin. It
will also be interesting to know if nucleolin plays an
essential role in radiation induced apoptosis. A nucleolin
overexpression and knock-out model will be highly valu-
able to address this issue. The role of each HSP70 func-
tional domain in protecting C23 are still yet to be
determined.
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